

October 28, 2026**BSE Limited**Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001**National Stock Exchange of India Limited**Exchange Plaza, C-1, Block G,
Bandra-Kurla Complex,
Bandra (East), Mumbai 400 051**Scrip Code: 544184****Trading Symbol: BOROSCI**

Dear Sirs,

Sub: Outcome of the Board Meeting

In furtherance of our intimation dated October 21, 2026, we hereby inform you that the Board of Directors of the Company at its meeting held today, i.e. October 28, 2026, has, *inter alia*, considered and approved the following:

- (a) Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026.

The aforesaid Financial Results along with Limited Review Reports of the Statutory Auditor are attached and are also made available on the Company's website at www.borosilscientific.com.

- (b) The proposal for setting up a Brosilicate 3.3 glass tubing furnace at the Company's Bharuch plant.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI's Master Circular updated as on January 30, 2026, are provided in **Annexure**.

The meeting of the Board of Directors commenced at 03:09 p.m. (IST) and concluded at 04:45 p.m. (IST).

Yours faithfully,

For **Borosil Scientific Limited**RAMAVTAR
RAMNIWAS
SHARMA Digitally signed by RAMAVTAR
RAMNIWAS SHARMA
Date: 2026.10.28 17:40:12
+05'30'**Ramavtar Sharma****Company Secretary & Compliance Officer**

Annexure

Sr. No.	Particulars	Details
1.	Existing capacity	Nil
2.	Existing capacity utilization	Not Applicable
3.	Proposed capacity addition	Setting up a Borosilicate 3.3 glass tubing furnace with an installed production capacity of around 20 Metric Tonnes (MT) per day.
4.	Period within which the proposed capacity is to be added	Commercial production is expected to commence by March 31, 2028.
5.	Investment required	Capital expenditure of up to Rs. 70 crores.
6.	Mode of financing	Internal accruals and / or Borrowings
7.	Rationale	Glass tubing is one of the main components used as a raw material for the Company's various glassware products and is presently procured from overseas suppliers. The project is intended to establish backward integration, reduce dependence on imported tubing, improve supply-chain reliability and control over quality and availability, and potentially optimise manufacturing costs of glassware products. The glass tubing would primarily be used for captive consumption, with surplus production be sold in the external market. Further, the Company would apply for the subsidy benefits on the eligible investment, as may be available under the Viksit Gujarat Industrial Policy 2026.

Independent Auditor's Review Report on Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,

**The Board of Directors of
Borosil Scientific Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Borosil Scientific Limited** ("the Company") for the quarter and half year ended 30th September 2026 ("the statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations"), as amended.
2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making enquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi & Shah LLP

Chartered Accountants

Registration No. 101720W/W100355

Anuj Bhatia

Partner

Membership No. 122179

UDIN No: 26122179SYJCEX4703



Place: Mumbai

Date: 28th October, 2026

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2026
(Rs. in lakhs except as stated)

S. No.	Particulars	Standalone					
		Quarter ended			Half Year ended		Year ended
		(30/09/2026)	(30/06/2026)	(30/09/2025)	(30/09/2026)	(30/09/2025)	(31/03/2026)
I.	Income:						
	Revenue From Operations	10,419.39	9,989.68	9,948.14	20,409.07	18,849.09	42,753.08
	Other Income	262.04	279.62	236.60	541.66	542.64	1,018.42
	Total Income (I)	10,681.43	10,269.30	10,184.74	20,950.73	19,391.73	43,771.50
II.	Expenses:						
	Cost of Materials Consumed	3,893.96	3,896.58	3,634.54	7,790.54	6,700.07	14,486.60
	Purchases of Stock-in-Trade	59.34	39.17	131.94	98.51	280.64	596.29
	Changes in Inventories of Work-in-progress, Finished Goods and Stock-in-trade	(439.14)	(869.06)	(270.97)	(1,308.20)	(396.09)	(145.70)
	Employee Benefits Expense	1,808.09	1,795.05	1,605.18	3,603.14	3,170.48	6,453.05
	Finance Costs	8.20	10.45	9.19	18.65	27.38	42.12
	Depreciation and Amortization Expense	480.50	444.91	438.83	925.41	885.51	1,752.11
	Other Expenses	3,977.38	4,021.09	3,622.75	7,998.47	6,982.90	14,359.63
	Total Expenses (II)	9,788.33	9,338.19	9,171.46	19,126.52	17,650.89	37,544.10
III.	Profit Before Exceptional Items and Tax (I - II)	893.10	931.11	1,013.28	1,824.21	1,740.84	6,227.40
IV.	Exceptional Items (Refer Note 2)	-	-	-	-	661.31	852.82
V.	Profit Before Tax (III - IV)	893.10	931.11	1,013.28	1,824.21	1,079.53	5,374.58
VI.	Tax Expense:						
	(1) Current Tax	291.84	175.48	308.38	467.32	308.38	1,441.35
	(2) Deferred Tax	(23.72)	71.28	(47.16)	47.56	(26.67)	(39.23)
	Total Tax Expenses	268.12	246.76	261.22	514.88	281.71	1,402.12
VII.	Profit for the Period / Year (V - VI)	624.98	684.35	752.06	1,309.33	797.82	3,972.46
VIII.	Other Comprehensive Income (OCI)						
	Items that will not be reclassified to profit or loss:						
	a) Re-measurement gains / (losses) on defined benefit plans	(8.57)	(8.41)	1.99	(16.98)	4.46	(61.35)
	b) Income tax effect on above	2.15	2.12	(0.50)	4.27	(1.12)	15.44
	Total Other Comprehensive Income	(6.42)	(6.29)	1.49	(12.71)	3.34	(45.91)
IX.	Total Comprehensive Income for the Period / Year (VII + VIII)	618.56	678.06	753.55	1,296.62	801.16	3,926.55
X.	Paid-up Equity Share Capital (Face value of Re. 1/- each fully paid up)	889.52	889.47	889.47	889.52	889.47	889.47
XI.	Other Equity excluding Revaluation Reserve						44,190.79
XII.	Earning per equity share (in Rs.) (Face value of Re. 1/- each)						
	Basic (Not Annualised)*	0.70*	0.77*	0.85 *	1.47*	0.90 *	4.47
	Diluted (Not Annualised)*	0.70*	0.77*	0.85 *	1.47*	0.90 *	4.47



BOROSIL SCIENTIFIC LIMITED

UNAUDITED STANDALONE SEGMENT INFORMATION FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2026

(Rs. in lakhs)

S. No.	Particulars	Standalone					
		Quarter ended			Half Year ended		Year ended
		(30/09/2026)	(30/06/2026)	(30/09/2025)	(30/09/2026)	(30/09/2025)	(31/03/2026)
1	Segment Revenue :						
	a. Scientific – Laboratory Glass & Equipment and Process System	6,828.31	6,153.47	6,573.41	12,981.78	12,261.24	29,717.56
	b. Primary Pharma Packaging	2,095.55	2,306.66	1,725.85	4,402.21	3,478.43	7,033.85
	c. Consumer Glassware	1,495.53	1,529.55	1,648.88	3,025.08	3,109.42	6,001.67
	Total	10,419.39	9,989.68	9,948.14	20,409.07	18,849.09	42,753.08
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Revenue from operations	10,419.39	9,989.68	9,948.14	20,409.07	18,849.09	42,753.08
2	Segment Results (Profit before tax):						
	a. Scientific – Laboratory Glass & Equipment and Process System	1,439.68	1,289.04	1,805.98	2,728.72	3,129.12	8,792.87
	b. Primary Pharma Packaging	(260.46)	(53.81)	(513.23)	(314.27)	(822.97)	(1,442.26)
	c. Consumer Glassware	78.49	80.30	86.57	158.79	163.24	315.09
	Total	1,257.71	1,315.53	1,379.32	2,573.24	2,469.39	7,665.70
	Less:- Finance Cost	8.20	10.45	9.19	18.65	27.38	42.12
	Less: Exceptional Items (Refer Note 2)	-	-	-	-	661.31	852.82
	Less:- Other unallocable expenditure (net of income)	356.41	373.97	356.85	730.38	701.17	1,396.18
	Profit before tax	893.10	931.11	1,013.28	1,824.21	1,079.53	5,374.58
3	Segment Assets						
	a. Scientific – Laboratory Glass & Equipment and Process System	16,969.39	16,201.97	15,976.88	16,969.39	15,976.88	17,703.50
	b. Primary Pharma Packaging	9,984.27	9,693.93	7,989.58	9,984.27	7,989.58	9,156.94
	c. Consumer Glassware	2,713.84	2,555.27	2,442.33	2,713.84	2,442.33	2,411.97
	d. Un-allocated	26,163.52	26,999.25	23,861.63	26,163.52	23,861.63	25,650.20
	Total	55,831.02	55,450.42	50,270.42	55,831.02	50,270.42	54,922.61
4	Segment Liabilities						
	a. Scientific – Laboratory Glass & Equipment and Process System	4,677.92	4,927.11	3,995.75	4,677.92	3,995.75	5,041.41
	b. Primary Pharma Packaging	1,730.71	1,457.38	1,085.75	1,730.71	1,085.75	1,813.65
	c. Consumer Glassware	619.55	824.04	871.77	619.55	871.77	625.35
	d. Un-allocated	1,253.37	1,350.92	1,361.04	1,253.37	1,361.04	1,263.65
	Total	8,281.55	8,559.45	7,314.31	8,281.55	7,314.31	8,744.06

Note : 1

As per Indian Accounting Standard 108 on 'Operating Segment' (Ind-AS 108), the Company has reported "Segment information", as described below:

Scientific – Laboratory Glass & Equipment and Process System:- Comprising of items used in laboratories, production floor and research and development and filter paper.

Primary Pharma Packaging :- Comprising of Tabular Vials and Ampoules used as Primary Pharma Packaging material in Pharmaceutical Companies.

Consumer Glassware:- Comprising of Consumer glassware items.

Unallocated:- Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.

Note : 2

During the quarter ended 30th September, 2026, in view of the expansion of the Consumer Glassware business, the internal reporting structure has been changed so that the Chief Operating Decision Maker (CODM) reviews the performance of Consumer Glassware separately for allocating resources and assessing performance. Consequently, the Company has re-assessed and realigned its operating segments in accordance with Ind AS 108 "Operating Segments". Accordingly, the segments of the Company, which were earlier reported as (a) Scientific – Laboratory Glass & Equipment and Process System, (b) Glassware and (c) Others, are now reported as (a) Scientific – Laboratory Glass & Equipment and Process System, (b) Primary Pharma Packaging and (c) Consumer Glassware. In accordance with paragraph 29 of Ind AS 108, the segment information for the corresponding previous periods / year has been restated, and the figures have been rearranged / reclassified to conform to the revised segment structure



BOROSIL SCIENTIFIC LIMITED

UNAUDITED STANDALONE BALANCE SHEET AS AT 30TH SEPTEMBER, 2026

Particulars	(Rs. in lakhs)	
	Standalone	
	As at (30/09/2026)	As at (31/03/2026)
I. ASSETS		
1 Non-current Assets		
(a) Property, Plant and Equipment	10,760.80	9,614.94
(b) Capital work-in-progress	93.50	877.05
(c) Goodwill on Amalgamation	5,931.84	5,931.84
(d) Other Intangible assets	81.27	98.63
(e) Intangible assets under development	1.88	3.16
(f) Financial Assets		
(i) Investments	5,246.48	5,246.48
(ii) Loans	982.69	636.40
(iii) Others	268.74	228.17
(g) Non Current Tax Assets (net)	290.35	34.17
(h) Other non current assets	1,118.45	280.96
Total non current assets	24,776.00	22,951.80
2 Current Assets		
(a) Inventories	11,281.89	9,499.50
(b) Financial Assets		
(i) Investments	12,292.34	12,243.92
(ii) Trade Receivables	4,668.85	7,186.01
(iii) Cash and cash equivalents	1,101.75	1,268.39
(iv) Bank Balances other than (iii) above	22.74	17.18
(v) Loans	54.43	54.64
(vi) Others	420.36	633.04
(c) Other current assets	1,212.66	1,068.13
Total current assets	31,055.02	31,970.81
TOTAL ASSETS	55,831.02	54,922.61
II. EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	889.52	889.47
(b) Other Equity	46,659.95	45,289.08
Total equity	47,549.47	46,178.55
LIABILITIES		
1 Non current Liabilities		
(a) Financial Liabilities		
(i) Lease Liabilities	59.63	57.37
(b) Deferred Tax Liabilities (net)	984.10	940.81
Total non current liabilities	1,043.73	998.18
2 Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	30.71	30.71
(ii) Trade Payables		
A) Total outstanding dues of micro and small enterprises	1,022.09	1,164.79
B) Total outstanding dues of creditors other than micro and small enterprises	2,036.32	2,839.00
(iii) Other Financial Liabilities	2,439.23	1,893.60
(b) Other current liabilities	711.63	907.96
(c) Provisions	908.70	806.21
(d) Current Tax Liabilities (net)	89.14	103.61
Total current liabilities	7,237.82	7,745.88
TOTAL EQUITY AND LIABILITIES	55,831.02	54,922.61



BOROSIL SCIENTIFIC LIMITED

UNAUDITED STANDALONE STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30TH
SEPTEMBER, 2026

		(Rs. in lakhs)	
Particulars		For the Half Year Ended	For the Half Year Ended
		(30/09/2026)	(30/09/2025)
A. Cash Flow from Operating Activities			
Profit Before Tax as per Statement of Profit and Loss		1,824.21	1,079.53
Adjusted for :			
Depreciation and Amortisation Expense		925.41	885.51
Loss / (Gain) on Foreign Currency Transactions (net)		0.37	(16.73)
Loss / (Gain) on Financial Instruments measured at fair value through profit or loss (net)		(396.88)	(327.16)
Loss / (Gain) on Sale of Investments (net)		(51.54)	(36.32)
Interest Income		(47.49)	(56.10)
Loss / (Gain) on Sale / discarding of Property, Plant and Equipment		0.27	55.29
Share Based Payment Expense		59.86	108.67
Finance Costs		18.65	27.38
Sundry Balances / Excess Provision Written Back (net)		(0.02)	(1.86)
Allowance/(reversal) for Expected Credit Losses / Doubtful Advances (net)		24.00	(5.75)
Operating Profit before Working Capital Changes		2,356.84	1,712.46
Adjusted for :			
Trade and Other Receivables		2,516.99	1,220.59
Inventories		(1,782.39)	(717.06)
Trade and Other Payables		(581.04)	(236.94)
Cash generated from / (used in) operations		2,510.40	1,979.05
Direct Taxes Paid (net)		(737.97)	(716.56)
Net Cash From / (Used in) Operating Activities		1,772.43	1,262.49
B. Cash Flow from Investing Activities			
Purchase of Property, Plant and Equipment and Intangible Assets		(2,026.51)	(890.46)
Sale of Property, Plant and Equipment (net)		0.89	52.55
Purchase of Current Investments		(1,300.00)	(1,900.00)
Sale of Current Investments		1,700.00	2,000.00
Fixed Deposit Placed		(5.27)	(5.27)
Loans to Subsidiary		(350.00)	(878.00)
Interest Income		46.54	26.45
Net Cash From / (Used in) Investing Activities		(1,934.35)	(1,594.74)
C. Cash Flow from Financing Activities			
Proceeds from issue of Share Capital		7.53	15.28
Repayment of Non-current Borrowings		-	(52.60)
Movement in Current Borrowings (net)		-	(252.64)
Lease Payments		-	(31.49)
Margin Money (net)		4.98	139.33
Interest Paid		(17.16)	(28.29)
Net Cash From / (Used in) Financing Activities		(4.65)	(210.41)
Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)		(166.57)	(542.65)
Opening Balance of Cash and Cash Equivalents		1,268.39	1,324.70
Unrealised Gain/(loss) on Foreign Currency Transactions (net)		0.09	0.09
Opening Balance of Cash and Cash Equivalents		1,268.30	1,324.61
Closing Balance of Cash and Cash Equivalents		1,101.75	782.08
Unrealised Gain/(loss) on Foreign Currency Transactions (net)		0.02	0.12
Closing Balance of Cash and Cash Equivalents		1,101.73	781.96



Notes on Unaudited Standalone Financial Results for the quarter and half year ended 30th September, 2026:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 28th October, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the above results.
2. Exceptional items comprise: i) Rs. 661.31 lakhs for the half year ended 30th September, 2025 and the year ended 31st March, 2026, representing expenditure incurred towards the Voluntary Retirement Scheme (VRS) for eligible workers at the Company's plant located at Village Ambad, Nashik, Maharashtra and ii) Rs. 191.51 lakhs for the year ended 31st March, 2026, representing the one-time incremental impact arising from the implementation of the new Labour Codes.
3. Pursuant to exercise of the options issued under "BSL – Employee Stock Option Scheme (BSL – ESOS)", the Company has made allotment of 4475 Equity Shares of the face value of Re. 1/- each for the quarter and half year ended 30th September, 2026, which has resulted into increase of paid up Equity Share Capital by Rs. 0.05 lakhs and Securities Premium by Rs. 7.48 lakhs.
4. The figures for the corresponding previous period/year have been rearranged/ regrouped, wherever necessary, to make them comparable.

For Borosil Scientific LimitedPlace: Mumbai
Date : 28th October, 2026**Vinayak Patankar**
Whole-time Director & CEO
(DIN 07534225)

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,

**The Board of Directors of
Borosil Scientific Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Borosil Scientific Limited** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together refer to as "the Group") for the quarter and half year ended 30th September, 2026 ("the statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ("the Listing Regulation"), as amended.
2. This statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular no. CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Listing Regulations, as amended, to the extent applicable.

4. The statement includes the results of its subsidiary Goel Scientific Glass Works Limited.
5. Based on our review conducted as above and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial result includes the interim financial results of 1 subsidiary, whose interim financial results reflect total assets of Rs. 4,306.91 Lakhs as at 30th September, 2026, total revenue of Rs. 1,127.90 Lakhs and Rs. 1,890.72 Lakhs, total net profit/(loss) after tax of Rs. (84.87) Lakhs and Rs. (321.05) Lakhs and total comprehensive income of Rs. (83.66) Lakhs and Rs. (318.77) Lakhs for the quarter ended 30th September, 2026 and for the period from 1st April, 2026 to 30th September, 2026 respectively, and cash outflow (net) of Rs. 39.38 Lakhs for the period from 1st April, 2026 to 30th September, 2026, as considered in the unaudited consolidated financial results. The interim results of the above subsidiary have been reviewed by other auditor, whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to amount and disclosures included in respect of that subsidiary is based solely on the report of the other auditor and procedures performed by us as stated in paragraph 3 above.



Our conclusion on the statement is not modified in respect of the above matter with respect to our reliance on the work done and the report of other auditor.

For Chaturvedi & Shah LLP

Chartered Accountants

Registration No. 101720W/W100355

Anuj Bhatia

Partner

Membership No. 122179

UDIN No: 26122179KRVYLX8323



Place: Mumbai

Date: 28th October 2026

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2026

(Rs. in lakhs except as stated)

S. No.	Particulars	Consolidated					
		Quarter ended			Half Year ended		Year ended
		(30/09/2026)	(30/06/2026)	(30/09/2025)	(30/09/2026)	(30/09/2025)	(31/03/2026)
I.	Income:						
	Revenue From Operations	11,496.37	10,675.23	10,689.88	22,171.60	20,287.52	46,734.15
	Other Income	240.77	266.64	214.97	507.41	506.77	954.59
	Total Income (I)	11,737.14	10,941.87	10,904.85	22,679.01	20,794.29	47,688.74
II.	Expenses:						
	Cost of Materials Consumed	4,323.60	4,100.59	3,922.31	8,424.19	7,277.57	15,843.99
	Purchases of Stock-in-Trade	59.34	44.93	235.55	104.27	445.58	1,128.58
	Changes in Inventories of Work-in-progress, Finished Goods and Stock-in-trade	(438.13)	(813.62)	(291.10)	(1,251.75)	(400.59)	(288.44)
	Employee Benefits Expense	2,189.37	2,197.73	2,064.01	4,387.10	4,069.76	8,020.38
	Finance Costs	21.51	25.47	22.63	46.98	61.00	112.80
	Depreciation and Amortization Expense	522.47	488.73	481.46	1,011.20	969.08	1,923.88
	Other Expenses	4,291.88	4,299.97	3,956.51	8,591.85	7,605.30	15,810.27
	Total Expenses (II)	10,970.04	10,343.80	10,391.37	21,313.84	20,027.70	42,551.46
III.	Profit before share of profit in associate, exceptional items and tax (I - II)	767.10	598.07	513.48	1,365.17	766.59	5,137.28
IV.	Share of profit in associates	-	-	-	-	-	-
V.	Profit before Exceptional Items and tax (III + IV)	767.10	598.07	513.48	1,365.17	766.59	5,137.28
VI.	Exceptional Items (Refer Note 2)	-	-	-	-	661.31	852.82
VII.	Profit Before Tax (V - VI)	767.10	598.07	513.48	1,365.17	105.28	4,284.46
VIII.	Tax Expense:						
	(1) Current Tax	291.84	175.48	308.38	467.32	308.38	1,441.35
	(2) Deferred Tax	(55.40)	(12.92)	(79.64)	(68.32)	(66.88)	(615.01)
	Total Tax Expenses	236.44	162.56	228.74	399.00	241.50	826.34
IX.	Profit / (Loss) for the Period / Year (VII - VIII)	530.66	435.51	284.74	966.17	(136.22)	3,458.12
X.	Other Comprehensive Income (OCI)						
	Items that will not be reclassified to profit or loss:						
	a) Re-measurement gains / (losses) on defined benefit plans	(6.95)	(6.98)	(2.48)	(13.93)	(4.48)	(4.01)
	b) Income tax effect on above	1.74	1.76	0.63	3.50	1.13	1.01
	Total Other Comprehensive Income	(5.21)	(5.22)	(1.85)	(10.43)	(3.35)	(3.00)
XI.	Total Comprehensive Income for the period / year (IX + X)	525.45	430.29	282.89	955.74	(139.57)	3,455.12
XII.	Profit / (Loss) attributable to:						
	Owners of the Company	531.25	437.08	289.27	968.33	(127.16)	3,461.36
	Non-controlling interest	(0.59)	(1.57)	(4.53)	(2.16)	(9.06)	(3.24)
XIII.	Other Comprehensive Income attributable to:						
	Owners of the Company	(5.21)	(5.23)	(1.82)	(10.44)	(3.29)	(3.27)
	Non-controlling interest	(0.00)	0.01	(0.03)	0.01	(0.06)	0.27
XIV.	Total Comprehensive Income attributable to:						
	Owners of the Company	526.04	431.85	287.45	957.89	(130.45)	3,458.09
	Non-controlling interest	(0.59)	(1.56)	(4.56)	(2.15)	(9.12)	(2.97)
XV.	Paid-up Equity Share Capital (Face value of Re. 1/- each fully paid up)	889.52	889.47	889.47	889.52	889.47	889.47
XVI.	Other Equity excluding Revaluation Reserve						42,142.96
XVII.	Earning per equity share (in Rs.) (Face value of Re. 1/- each)						
	Basic (Not Annualised)*	0.60*	0.49 *	0.32*	1.09 *	(0.14) *	3.89
	Diluted (Not Annualised)*	0.60*	0.49 *	0.32*	1.09 *	(0.14) *	3.89



BOROSIL SCIENTIFIC LIMITED

UNAUDITED CONSOLIDATED SEGMENT INFORMATION FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2026

(Rs. in lakhs)

S. No.	Particulars	Consolidated					
		Quarter ended			Half Year ended		Year ended
		(30/09/2026)	(30/06/2026)	(30/09/2025)	(30/09/2026)	(30/09/2025)	(31/03/2026)
1	Segment Revenue :						
	a. Scientific – Laboratory Glass & equipment and Process System	7,905.29	6,839.02	7,298.85	14,744.31	13,672.84	33,654.84
	b. Primary Pharma Packaging	2,095.55	2,306.66	1,725.85	4,402.21	3,478.43	7,033.85
	c. Consumer Glassware	1,495.53	1,529.55	1,665.18	3,025.08	3,136.25	6,045.46
	Total	11,496.37	10,675.23	10,689.88	22,171.60	20,287.52	46,734.15
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Revenue from operations	11,496.37	10,675.23	10,689.88	22,171.60	20,287.52	46,734.15
2	Segment Results (Profit /(Loss) before tax and non-controlling interests):						
	a. Scientific – Laboratory Glass & equipment and Process System	1,326.99	971.02	1,300.58	2,298.01	2,156.19	7,720.65
	b. Primary Pharma Packaging	(260.46)	(53.81)	(513.23)	(314.27)	(822.97)	(1,442.26)
	c. Consumer Glassware	78.49	80.30	105.61	158.79	195.54	367.87
	Total	1,145.02	997.51	892.96	2,142.53	1,528.77	6,646.26
	Less:- Finance Cost	21.51	25.47	22.63	46.98	61.00	112.80
	Less:- Exceptional Items (Refer Note 2)	-	-	-	-	661.31	852.82
	Less:- Other unallocable expenditure (net of income)	356.41	373.97	356.85	730.38	701.18	1,396.18
	Profit / (Loss) before Tax	767.10	598.07	513.48	1,365.17	105.28	4,284.46
3	Segment Assets						
	a. Scientific – Laboratory Glass & equipment and Process System	21,246.80	20,662.97	20,803.05	21,246.80	20,803.05	22,288.74
	b. Primary Pharma Packaging	9,984.27	9,693.93	7,989.58	9,984.27	7,989.58	9,156.94
	c. Consumer Glassware	2,713.84	2,555.27	2,442.33	2,713.84	2,442.33	2,411.97
	d. Un-allocated	21,316.43	22,113.91	19,012.22	21,316.43	19,012.22	21,050.61
	Total	55,261.34	55,026.08	50,247.18	55,261.34	50,247.18	54,908.26
4	Segment Liabilities						
	a. Scientific – Laboratory Glass & equipment and Process System	6,041.65	6,140.31	5,868.11	6,041.65	5,868.11	6,321.11
	b. Primary Pharma Packaging	1,730.71	1,457.38	1,085.75	1,730.71	1,085.75	1,813.65
	c. Consumer Glassware	619.55	824.04	871.77	619.55	871.77	625.35
	d. Un-allocated	1,690.13	1,990.44	1,964.03	1,690.13	1,964.03	1,998.89
	Total	10,082.04	10,412.17	9,789.66	10,082.04	9,789.66	10,759.00

Note 1 :

As per Indian Accounting Standard 108 on 'Operating Segment' (Ind-AS 108), the Group has reported "Segment information", as described below:

Scientific – Laboratory Glass & equipment and Process System:- Comprising of items used in laboratories, production floor and research and development and filter paper.

Primary Pharma Packaging :- Comprising of Tabular Vials and Ampoules used as Primary Pharma Packaging material in Pharmaceutical Companies.

Consumer Glassware:- Comprising of Consumer glassware items.

Unallocated:- Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.

Note 2 :

During the quarter ended 30th September, 2026, in view of the expansion of the Consumer Glassware business, the internal reporting structure has been changed so that the Chief Operating Decision Maker (CODM) reviews the performance of Consumer Glassware separately for allocating resources and assessing performance. Consequently, the Group has re-assessed and realigned its operating segments in accordance with Ind AS 108 "Operating Segments". Accordingly, the segments of the Group, which were earlier reported as (a) Scientific – Laboratory Glass & Equipment and Process System, (b) Glassware and (c) Others, are now reported as (a) Scientific – Laboratory Glass & Equipment and Process System, (b) Primary Pharma Packaging and (c) Consumer Glassware. In accordance with paragraph 29 of Ind AS 108, the segment information for the corresponding previous periods / year has been restated, and the figures have been rearranged / reclassified to conform to the revised segment structure.



BOROSIL SCIENTIFIC LIMITED

UNAUDITED CONSOLIDATED BALANCE SHEET AS AT 30TH SEPTEMBER, 2026

(Rs. in lakhs)

Particulars	Consolidated	
	As at	As at
	(30/09/2026)	(31/03/2026)
I. ASSETS		
1 Non-current Assets		
(a) Property, Plant and Equipment	13,252.37	12,163.07
(b) Capital work-in-progress	93.50	877.70
(c) Goodwill on Amalgamation	6,219.37	6,219.37
(d) Other Intangible assets	429.15	473.10
(e) Intangible assets under development	1.88	3.16
(f) Financial Assets		
(i) Investments	1.41	1.41
(ii) Loans	4.69	8.40
(iii) Others	279.03	238.56
(g) Deferred Tax Assets (net)	1,135.90	1,020.79
(h) Non Current Tax Assets (net)	290.35	34.17
(i) Other non current assets	1,183.35	328.24
Total non current assets	22,891.00	21,367.97
2 Current Assets		
(a) Inventories	12,126.72	10,324.87
(b) Financial Assets		
(i) Investments	12,292.34	12,243.92
(ii) Trade Receivables	4,939.94	7,572.63
(iii) Cash and cash equivalents	1,111.80	1,317.82
(iv) Bank Balances other than (iii) above	62.70	56.78
(v) Loans	54.43	54.64
(vi) Others	368.56	595.56
(c) Current Tax Assets (net)	5.26	4.80
(d) Other current assets	1,408.59	1,369.27
Total current assets	32,370.34	33,540.29
TOTAL ASSETS	55,261.34	54,908.26
II. EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	889.52	889.47
(b) Other Equity	44,273.39	43,241.25
Equity attributable to the owners	45,162.91	44,130.72
Non-controlling interest	16.39	18.54
Total equity	45,179.30	44,149.26
LIABILITIES		
1 Non current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	52.43	76.72
(ii) Lease Liabilities	59.63	57.37
(b) Provisions	389.82	406.04
(c) Deferred Tax Liabilities (net)	984.10	940.81
Total non current liabilities	1,485.98	1,480.94
2 Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	467.75	728.89
(ii) Trade Payables		
A) Total outstanding dues of micro and small enterprises	1,070.39	1,338.73
B) Total outstanding dues of creditors other than micro and small enterprises	2,051.55	2,910.05
(iii) Other Financial Liabilities	2,799.85	2,212.49
(b) Other current liabilities	1,156.41	1,125.81
(c) Provisions	960.97	858.48
(d) Current Tax Liabilities (net)	89.14	103.61
Total current liabilities	8,596.06	9,278.06
TOTAL EQUITY AND LIABILITIES	55,261.34	54,908.26



BOROSIL SCIENTIFIC LIMITED

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2026

(Rs. in lakhs)

Particulars	For the Half Year Ended	For the Half Year Ended
	(30/09/2026)	(30/09/2025)
A. Cash Flow from Operating Activities		
Profit Before Tax as per Statement of Profit and Loss	1,365.17	105.28
Adjusted for :		
Depreciation and Amortisation Expense	1,011.20	969.08
Loss / (Gain) on Foreign Currency Transactions (net)	0.76	(16.72)
Loss / (Gain) on Financial Instruments measured at fair value through profit or loss (net)	(396.88)	(327.16)
Loss / (Gain) on Sale of Investments (net)	(51.54)	(36.32)
Interest Income	(10.46)	(16.17)
Loss / (Gain) on Sale / discarding of Property, Plant and Equipment (net)	0.27	55.29
Share Based Payment Expense	66.84	119.77
Finance Costs	46.98	61.00
Sundry Balances / Excess Provision Written Back (net)	(0.02)	(1.86)
Provision / (Reversal) for Credit Impaired / Doubtful Advances (net)	45.92	(5.75)
Operating Profit before Working Capital Changes	2,078.24	906.44
Adjusted for :		
Trade and Other Receivables	2,701.75	1,323.35
Inventories	(1,801.85)	(670.61)
Trade and Other Payables	(509.79)	(67.05)
Cash generated from operations	2,468.35	1,492.13
Direct Taxes Paid (net)	(738.43)	(717.57)
Net Cash From / (Used in) Operating Activities	1,729.92	774.56
B. Cash Flow from Investing Activities		
Purchase of Property, Plant and Equipment and Intangible Assets	(2,029.30)	(1,008.25)
Sale of Property, Plant and Equipment (net)	1.45	52.55
Purchase of Current Investments	(1,300.00)	(1,900.00)
Sale of Current Investments	1,700.00	2,000.00
Fixed Deposit Placed	(7.04)	(5.27)
Interest Income	16.83	12.57
Net Cash From / (Used in) Investing Activities	(1,618.06)	(848.40)
C. Cash Flow from Financing Activities		
Proceeds of Equity Share Capital	7.53	15.28
Repayment of Non-current Borrowings	(39.18)	(104.39)
Movement in Current Borrowings (net)	(246.25)	(421.52)
Lease Payments	-	(31.49)
Margin Money (net)	2.89	138.92
Interest Paid	(42.79)	(62.12)
Net Cash From / (Used in) Financing Activities	(317.80)	(465.32)
Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)	(205.94)	(539.16)
Opening Balance of Cash and Cash Equivalents	1,317.82	1,332.37
Unrealised Gain/(loss) on Foreign Currency Transactions (net)	0.10	0.10
Opening Balance of Cash and Cash Equivalents	1,317.72	1,332.27
Closing Balance of Cash and Cash Equivalents	1,111.80	793.23
Unrealised Gain/(loss) on Foreign Currency Transactions (net)	0.02	0.12
Closing Balance of Cash and Cash Equivalents	1,111.78	793.11



Notes on Unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2026:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 28th October, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the above results.
2. Exceptional items comprise: i) Rs. 661.31 lakhs for the half year ended 30th September, 2025 and for the year ended 31st March, 2026, representing expenditure incurred towards the Voluntary Retirement Scheme (VRS) for eligible workers at the Company's plant located at Village Ambad, Nashik, Maharashtra and ii) Rs. 191.51 lakhs for the year ended 31st March, 2026, representing the one-time incremental impact arising from the implementation of the new Labour Codes.
3. Pursuant to exercise of the options issued under "BSL – Employee Stock Option Scheme (BSL – ESOS)", the Company has made allotment of 4475 Equity Shares of the face value of Re. 1/- each for the quarter and half year ended 30th September, 2026, which has resulted into increase of paid up Equity Share Capital by Rs. 0.05 lakhs and Securities Premium by Rs. 7.48 lakhs.
4. The figures for the corresponding previous period/year have been rearranged/ regrouped, wherever necessary, to make them comparable.

For **Borosil Scientific Limited**Place: Mumbai
Date : 28th October, 2026
Vinayak Patankar
Whole-time Director & CEO
(DIN 07534225)